Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

FLOWER-MI: FFR vs. Angiography for Complete Revascularization in Infarction

Functional assessment with fractional flow reserve (FFR) was not better than conventional angiography to guide complete revascularization in patients with multivessel lesions in a setting of ST-segment elevation myocardial infarction and successful primary angioplasty.

FLOWER-MI: FFR vs angiografía para revascularización completa en los infartos

These results were published in the New England Journal of Medicine (NEJM) and presented during the American College of Cardiology (ACC) 2021 Congress.

The rate of major cardiovascular events was low and similar between both strategies at a one-year follow-up. This would jeopardize the cost-benefit relationship of FFR in infarction.

Randomized and registry evidence is robust regarding FFR superiority vs. angiography in patients with chronic coronary syndromes.

In an acute context (especially in ST-segment elevation infarction), the COMPARE-ACUTE and DANAMI3-PRIMULTI studies showed that FFR-guided complete revascularization was superior to culprit-vessel angioplasty alone.

There is little information on FFR-guided complete revascularization vs. angiography-guided revascularization in ST-segment elevation infarction.

FLOWER-MI received some criticism from experts. On the one hand, the low incidence of events could take away some of its statistical power; on the other, non-culprit lesions seem particularly significant. In this sense, they do not appear to be typical intermediate lesions where FFR guide showed the greatest benefit.


Read also: Pfizer/BioNTech Vaccine against COVID-19 in Teenagers.


Another target of criticism was that operators performed the entire revascularization in the same procedure, something that is far from daily clinical practice.

These studies analyzed 1163 patients with acute myocardial infarction and multivessel lesion (mean age: 62.2 years) who underwent successful primary angioplasty in the culprit vessel randomized to FFR-guided vs. angiography-guided complete revascularization.

Angiography of non-culprit lesions was conducted in 66.2% of FFR-guided patients and in 97.1% of angiography-guided patients.


Read also: Myocarditis and Messenger RNA COVID-19 Vaccine: What Is the Risk?


The primary endpoint (a composite of death, infarction, or unplanned revascularization requiring hospitalization) was reached in 5.5% of patients the FFR arm vs. 4.2% in the angiography arm, a non-significant difference (hazard ratio: 1.32; 95% confidence interval: 0.78 to 2.23; p = 0.31). The statistics for the separate components of the primary endpoint were also similar, and so were the secondary endpoints (stent thrombosis, antianginal medication, quality of life, and readmissions).

nejmoa2104650

Original Title: Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. 

Reference: Etienne Puymirat et al. N Engl J Med. 2021 May 16. Online ahead of print. doi: 10.1056/NEJMoa2104650. The FLOWER-MI Study Investigators.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...